BrainsWay Ltd. announced on November 20, 2024, the publication of positive feasibility clinical data evaluating Deep Transcranial Magnetic Stimulation (Deep TMS) for peripheral neuropathic pain. The results were published in the Neuromodulation journal, detailing a double-blind, randomized crossover trial. This study included seventeen patients suffering from chronic neuropathic pain.
The study's findings indicated that active Deep TMS therapy significantly reduced "usual pain intensity" in patients compared to sham treatment. Furthermore, the therapy improved symptoms of anxiety and depression within the same patient population. These outcomes suggest a potential new application for Deep TMS technology.
BrainsWay's Deep TMS is not currently cleared by the FDA for the treatment of neuropathic pain. The company stated that these results are the most recent dataset in a growing portfolio of clinical evidence on the potential efficacy of Deep TMS in treating multiple brain-related indications. Additional research is planned to further explore these findings.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.